Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus reduced tacrolimus versus tacrolimus plus mycophenolate mofetil after de novo liver transplantation
2013-001191-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial comparing everolimus + reduced tacrolimus with Control: tacrolimus + mycophenolate mofetil (2 arms). Primary endpoint: Clinical renal benefit from randomization to week 52. Started Jun 2013; status: completed.
02
Drugs
everolimustacrolimusmycophenolate mofetil
Beyond the preview
Go deeper on 2013-001191-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001191-38.